Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AMRI Names CEO | Contract Pharma
Promotions & Moves

AMRI Names CEO

Mulhern succeeds Marth

Michael Mulhern has been appointed chief executive officer of AMRI, a portfolio company of The Carlyle Group and GTCR. He succeeds William S. Marth. Mr. Mulhern previously served as chief executive officer of Sterigenics International, a global provider of contract sterilization, gamma technologies and medical isotopes. Mr. Marth will remain with the company in an advisory role.

Stephen H. Wise, managing director and global head of healthcare for Carlyle, said, “Michael is a highly accomplished executive with a 30-year track record of value creation in the healthcare and distribution sectors. His role as a member of AMRI’s board of directors, coupled with his experience leading three private equity-backed companies, will make this a smooth transition.” 

Dean Mihas, managing director and head of healthcare for GTCR, said, “We thank Bill for his years of successful leadership of AMRI. Since joining the board of directors in 2012 and becoming CEO in 2014, Bill has been instrumental in building AMRI into a leading contract research, development and manufacturing organization. We wish him success in his future endeavors.” 

Since 2002, Mr. Mulhern has served as chief executive officer of three companies backed by GTCR: Sterigenics International, Fairmont Food Group, and American Sanitary. He previously held roles at Baxter International and Alliant Foodservice.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters